5.16 - Aaron Goodman UCSD
I travel to UCSD to interview Dr. Goodman about myeloma, celebrity oncology culture, his career, education, patient care, choosing a specialty and more.
Sep 29, 2022•1 hr 34 min
Plenary Session - inactive due to federal service
Dr Prasad currently serves as the Director of the Center for Biologics Evaluation and Resesarch (CBER) at the US FDA. The audio on this platform were posted before my FDA employment and do not necessarily represent the views of the FDA or the United States. This site will be inactive during my federal service.
A podcast on medicine, oncology, & health policy.
Host: Vinay Prasad, MD MPH from University of California San Francisco.
Tweet your feedback to @Plenary_Session or e-mail [email protected]
Episodes
5.15 - How To Apply For And Get Your Perfect First Job
Based on listener questions, I discuss how to apply for and get your first job.
Sep 21, 2022•36 min
Unspoken Rules of Oncology - Malignant BC Part 6
T.O. joins me for the missing episode. These are the unspoken rules of Oncology; We dive deeper into Malignant Book Club.
Sep 18, 2022•1 hr 3 min
Malignant Book Club - Episode 7 - famous trials
Timothee Olivier joins me for the 7th installment of our book-club We cover famous trials in oncology
Sep 09, 2022•42 min
5.12 - Academics Vs Industry - A.Goodman S.Loghavi D.Steensma V.P.
How do careers vary between the academy and industry? We have a panel of the best: Sanam Loghavi from MD Anderson, Aaron Goodman UCSD, and David Steensma Novartis (formerly Farber/ Mayo) and VP #Real talk
Sep 03, 2022•1 hr 30 min
5.11 - Malignant Book Club - Part 5
Timothee Olivier joinrs me as we explore part 3 of the book Crossover, sample size, observational vs RCTs
Aug 26, 2022•53 min
5.10 - Adam Cifu on clinical excellence
Adam Cifu is here to discuss clinical excellence and his new podcast
Aug 24, 2022•1 hr 8 min
5.09 - Malignant Book Club Part 4
T.O. joins me to grill me on the rest of Financial Conflict of Interest and Precision Oncology. We discuss the need for randomization, and when it can be omitted. A must listen for Oncology Fans.
Aug 22, 2022•1 hr
5.08 - LaceWing RCT Phase 3 Blood - Spin Cycle
VP discusses the LaceWing study in Blood. A Phase 3 RCT of GILT AZA vs AZA; Medical writers; confounding; table 1; balance; and so much more
Aug 18, 2022•34 min
5.07 - Plenary Session Alps Edition
Timothee Olivier joins me to discuss recent papers: IMPOWER10 Checkmate 816 Path CR/ EFS/ Surrogates Drug Dosing, cGCSF rules and more Bread and butter oncology
Aug 10, 2022•59 min
5.06 - POLO trial now has OS results - OMG
The POLO trial, which we first broke on PS Season 1- is back with null OS results. But the trial authors enter the spin cycle. VP goes line by line.
Jul 21, 2022•31 min
5.05 - Citations, Metrics, Rankings in Oncology & Medicine
VP explains H index, total cites, papers, US News and World Report rankings and how evaluates researchers and doctors.
Jul 18, 2022•37 min
5.04 - Echelon 1 reports OS benefit - But does it add up?
VP addresses what to do you if you get an idea from listening to the show, and deconstructs ECHELON-1. Instead of listening we highly recommend you watch the video on YouTube with graphics. This is worth the watch.
Jul 14, 2022•39 min
5.03 - VPs Grand Rounds Lecture - Evidence Based Medicine - Will it Survive?
How to think about when and how to do RCTs? What are the limitations to observational studies? Smoking. Parachutes. Dostarlimab. Guarantee Time Bias. Confounding. Multiple Hypothesis testing and more
Jul 13, 2022•51 min
5.02 - Listener Questions - Cancer & Evidence Philosophy - What this Pod Offers
I make the case why this podcast should be your go to for Med, Onc & Policy. I describe my philosophy of Evidence, Empiricism, and show how this connects to many oncology studies. I answer a bunch of Listener Questions
Jul 11, 2022•47 min
5.01 - How To Read Randomized Trials In Cancer
How to read randomized trials in cancer medicine. Phase 2 vs 3, control arm, crossover, post protocol, censoring (the basics), and how law professors and medical professors are different and why it matters.
Jul 07, 2022•38 min
Lies and Exaggerations about Kids Vaccines < 5 years Old is Bad Public Health
Lies and Exaggerations about Kids Vaccine I give examples, and show why they are lies
Jun 22, 2022•19 min
Enact Trial - Enza vs Active Surveillance in Localized Prostate Cancer
What happens when you treat people with $168,000 a year medicine when most of them will never need treatment, and all of them don't need treatment now
Jun 20, 2022•15 min
Kids Vaccine For Under 5 years Old
I take a deep dive into the data for the mRNA vaccines for kids under 5 years olds
Jun 18, 2022•43 min
H. Jack West; Lung Cancer; Podcasting; TeleHealth: PACIFIC; ADAURA;CM816: KN189
I sit down with H Jack West. City of Hope. Thoracic Oncology and we have a long discussion about trials; staging; PDL1 thresholds; Driver mutations and post protocol care; ADAURA; Adjuvant; & More
Jun 18, 2022•1 hr 17 min
QuANTUM - Quizartinib Front Line - Ethics of Global Trials
I discuss the timeline of Ratify and Quantum. Was this an ethical trial? Is it sufficient to say a trial is ethical because 50% of participants get something?
Jun 15, 2022•42 min
4.67 Teclistimab for R/R Multiple Myeloma
The drug has a high response rate and lots of infections, is it active? Yes; Efficacious? ???? I review ASCO2022 updates
Jun 09, 2022•38 min
4.66 PD1 Ab for MSI H Stage II/ III Rectal Cancer; A 100% CR rate??
Are the results from Luis Diaz as good as touted. What trial should they do going forward? A 100% CR rate in Stage II and III rectal cancer??
Jun 08, 2022•24 min
4.65 DESTINY BREAST 04 - A complex trial to deconstruct
My take on the standing ovation for DESTINY Breast 04 Traztuzumab Deruxtecan vs. Investigator choice after endocrine therapy and 1 or 2 chemotherapies for HER2 low
Jun 07, 2022•32 min
4.64 - DETERMINATION - Should we still use transplant Myeloma?
I break down Richardson, et al. NEJM DETERMINATION Transplanters are determined to keep going, should they be? Watch the videos b/c I have lots of great visuals My ASCO Coverage continues
Jun 06, 2022•32 min
4.63 - ASCO22 - DYNAMIC - Can CT DNA Allow us to Give Less Chemo in Stage II Colon Cancer
The second paper from #ASCO2022 #ASCO22 that I break down This is one of the most technical papers I breakdown on the channel CT DNA used to omit chemo in Stage II colon cancer Read the book Malignant if you learn from this Watch the YouTube Figures https://youtu.be/QxOBIi7I2BU
Jun 05, 2022•35 min
4.62 - SHINE - Ibrutinib BR vs BR; Limitations to the trial
Continuous vs. Fixed, 3 vs 2, PFS is the primary endpoint No OS Bad crossover Lots to discuss here I will be covering all the major ASCO papers on @PlenarySession Subscribe to my substack https://vinayprasadmdmph.substack.com/
Jun 04, 2022•18 min
4.61 - How CDC's Vaccine Safety Missed Cases Of Myocarditis
I am joined by Dr. Katie Sharff, infectious disease doc, to discuss two of her papers on myocarditis after COVID-19 vaccination. https://doi.org/10.1016/j.amjcard.2022.02.039 https://doi.org/10.1101/2021.12.21.21268209
May 27, 2022•55 min
4.60 - NEW JCO paper - AML, EFS, CR, CRi, and Surrogate validation - FDA & Methods
I get back to my roots; I explain surrogate validation and a new JCO paper from the FDA authors on EFS and OS in AML. You won't want to miss it
May 21, 2022•34 min
4.59 - How to be a better reader of case control studies
In this episode I dissect a test negative case control trial; I talk about a famous pancreas cancer study and I revisit the failure of Myeloma trialists
May 17, 2022•19 min
For the best experience, listen in Metacast app for iOS or Android
Open in Metacast